{"classes":[{"categories":[{"measurements":[{"comment":"No participants in this age group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"No participants in this age group.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Due to insufficient number of participants in this age group (only 1 participant), CV% could not be calculated.","groupId":"OG002","spread":"NA","value":"2.5"},{"comment":"Due to insufficient number of participants in this age group (only 1 participant), CV% could not be calculated.","groupId":"OG003","spread":"NA","value":"1.8"}]}],"title":"Infants and Toddlers (age<2yr; n=0; n=0; n=1; n=1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.0","value":"2.4"},{"groupId":"OG001","spread":"1.9","value":"3.9"},{"groupId":"OG002","spread":"3.5","value":"4.6"},{"groupId":"OG003","spread":"1.9","value":"3.2"}]}],"title":"Children (age>=2 & <12yr; n=10; n=14; n=7; n=5)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.6","value":"3.7"},{"groupId":"OG001","spread":"0.5","value":"5.1"},{"groupId":"OG002","spread":"2.5","value":"4.5"},{"groupId":"OG003","spread":"2.9","value":"3.5"}]}],"title":"Adolescents (age>=12 & <18yr; n=8; n=5; n=7; n=2)"},{"categories":[{"measurements":[{"comment":"No participants in this age group.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Due to insufficient number of participants in this age group (only 1 participant), CV% could not be calculated.","groupId":"OG001","spread":"NA","value":"7.3"},{"comment":"No participants in this age group.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"No participants in this age group.","groupId":"OG003","spread":"NA","value":"NA"}]}],"title":"Above 18 years (n=0; n=1; n=0; n=0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.4","value":"3.0"},{"groupId":"OG001","spread":"1.8","value":"4.4"},{"groupId":"OG002","spread":"2.9","value":"4.4"},{"groupId":"OG003","spread":"1.9","value":"3.1"}]}],"title":"Total"}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"8"}],"units":"Participants"}],"description":"PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.","dispersionType":"Standard Deviation","groups":[{"description":"Dasatinib 60 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG000","title":"Dasatinib 60 mg/m^2"},{"description":"Tablets, Oral; If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Dasatinib 80 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG001","title":"Dasatinib 80 mg/m^2"},{"description":"Tablets, Oral; If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Dasatinib 100 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG002","title":"Dasatinib 100 mg/m^2"},{"description":"Tablets, Oral; If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Dasatinib 120 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG003","title":"Dasatinib 120 mg/m^2"}],"paramType":"MEAN","populationDescription":"All treated participants with plasma samples available. n=number of PK parameters included. Each participant could have more than 1 plasma profiles sampled, depending on the number of times the dose of dasatinib was escalated.","reportingStatus":"POSTED","timeFrame":"During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).","title":"Dasatinib Plasma Pharmacokinetic Parameter: Terminal Half-life (T 1/2) by Dose Level and Age Group","type":"SECONDARY","unitOfMeasure":"hour"}